Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Based on the results of pill count, the compliance rates were 92.9, 91.7, and 90.5% for the Placbo group, Low TT group, and High TT group respectively, showing no significant difference among the groups.Baseline demographic characteristics of study populationVariablesPlaceboLow TTHigh TTP valueNumber282930Age [y]59.4±6.358.5±6.761.2±7.20.431Weight [kg]74.3±17.976.3±14.874.3±16.80.680Height [cm]160.0±6.2163.7±6.5155.6±27.10.107Body mass index [kg/m2]28.9±6.528.5±5.028.8±5.80.986Bone mineral density [T-score] Femoral Neck−1.66±0.65−1.52±0.82−1.34±1.170.795 Trochanter−1.06±0.95−1.04±0.79−0.85±1.300.945 Total spine0.79±0.89−0.87±0.85−0.53±1.100.654 L1-L4−0.67±0.99−0.72±1.170.59±1.230.919Serum 25 (OH)D [ng/mL]35.79±9.1335.45±9.7034.27±9.970.634Serum TSH [mIU/L]2.25±1.012.45±1.462.52±1.710.944Serum HbA1c [%]5.66±0.355.81±0.345.56±0.360.011Medical history [n (%)] Broken bone as adult6 (21.43)7 (24.14)8 (26.67)0.897 Osteoarthritis3 (12.00)5 (20.83)3 (11.54)0.584 Diabetes2 (7.14)2 (6.90)0 (0.00)0.331 Asthma4 (14.29)3 (10.34)2 (6.67)0.636 Use of HRT in the past 2 yr10 (35.71)8 (27.59)6 (20.00)0.409 Steroid or glucocorticoid use5 (17.86)4 (13.79)3 (10.00)0.687 Prescribed osteoporosis drugs1 (3.57)4 (13.79)7 (23.33)0.093All data are mean ± standard deviation unless otherwise specifiedHbA1c hemoglobin A1c, High TT tocotrienol supplementation at 860 mg daily (70% purity); HRT hormone replacement treatment, Low TT tocotrienol supplementation at 430 mg daily (70% purity), TSH thyroid stimulating hormone, 25(OH)D 25-hydroxy-vitamin D
Source: Participants. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Double-blind reported · Human research reported
Reported blinded roles: participants, investigators.
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Eighty nine postmenopausal osteopenic women were randomly assigned to 3 treatment arms: (1) Placebo (430 mg olive oil/day), (2) Low tocotrientol (Low TT) (430 mg tocotrienol/day from DeltaGold 70 containing 300 mg tocotrienol) and (3) High tocotrienol (High TT) (860 mg tocotrienol/day from DeltaGold 70 containing 600 mg tocotrienol) for 12 weeks.
Source: Abstract.
This was a 12-week, double-blinded, placebo-controlled, randomized intervention trial to investigate the effects of tocotrienol on bone parameters.
Source: Methods.
The study participants and investigators were blinded to the group allocation.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
A 12-week evaluation of annatto tocotrienol supplementation for postmenopausal women: safety, quality of life, body composition, physical activity, and nutrient intake
Study design awaiting verification · BMC Complementary and Alternative Medicine · 2018
Original publication title
A 12-week evaluation of annatto tocotrienol supplementation for postmenopausal women: safety, quality of life, body composition, physical activity, and nutrient intake
© The Author(s). 2018
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Evidence suggests that tocotrienols may benefit bone health in osteopenic women. However, their safety in this population has never been investigated. This study was to evaluate the safety of a 12-week supplementation of annato tocotrienol in postmenopausal osteopenic women, along with effects of the supplementation on quality of life, body composition, physical activity, and nutrient intake in this population.
Source: BackgroundAbstract: What methods does the paper describe?
Eighty nine postmenopausal osteopenic women were randomly assigned to 3 treatment arms: (1) Placebo (430 mg olive oil/day), (2) Low tocotrientol (Low TT) (430 mg tocotrienol/day from DeltaGold 70 containing 300 mg tocotrienol) and (3) High tocotrienol (High TT) (860 mg tocotrienol/day from DeltaGold 70 containing 600 mg tocotrienol) for 12 weeks. DeltaGold 70 is an extract from annatto seed with 70% tocotrienol consisting of 90% delta-tocotrienol and 10% gamma-tocotrienol. Safety was examined by assessing liver enzymes (aspartate aminotransferase, alanine aminotransferase), alkaline phosphatase, bilirubin, kidney function (blood urea nitrogen and creatinine), electrolytes, glucose, protein, albumin, and globulin at 0, 6, and 12 weeks.
Serum tocotrienol and tocopherol concentrations were assessed and pills counted at 0, 6, and 12 weeks. Quality of life, body composition, physical activity, and dietary macro: and micro-nutrient intake were evaluated at 0 and 12 weeks. A mixed model of repeated measures ANOVA was applied for analysis.
Source: MethodsAbstract: Results
Eighty seven subjects completed the study. Tocotrienol supplementation did not affect liver or kidney function parameters throughout the study. No adverse event due to treatments was reported by the participants. Tocotrienol supplementation for 6 weeks significantly increased serum delta-tocotrienol level and this high concentration was sustained to the end of study. There was no difference in serum delta-tocotrienol levels between the Low TT and the High TT groups. No effects of tocotrienol supplementation were observed on quality of life, body composition, physical activity, and nutrient intake.
Source: ResultsAbstract: Conclusions
Annatto-derived tocotrienol up to 600 mg per day for 12 weeks appeared to be safe in postmenopausal osteopenic women, particularly in terms of liver and kidney functions. Tocotrienol supplementation for 12 weeks did not affect body composition, physical activity, quality of life, or intake of macro: and micro-nutrients in these subjects.
Source: ConclusionsAuthors’ abstract
Background
Evidence suggests that tocotrienols may benefit bone health in osteopenic women. However, their safety in this population has never been investigated. This study was to evaluate the safety of a 12-week supplementation of annato tocotrienol in postmenopausal osteopenic women, along with effects of the supplementation on quality of life, body composition, physical activity, and nutrient intake in this population.
Methods
Eighty nine postmenopausal osteopenic women were randomly assigned to 3 treatment arms: (1) Placebo (430 mg olive oil/day), (2) Low tocotrientol (Low TT) (430 mg tocotrienol/day from DeltaGold 70 containing 300 mg tocotrienol) and (3) High tocotrienol (High TT) (860 mg tocotrienol/day from DeltaGold 70 containing 600 mg tocotrienol) for 12 weeks. DeltaGold 70 is an extract from annatto seed with 70% tocotrienol consisting of 90% delta-tocotrienol and 10% gamma-tocotrienol. Safety was examined by assessing liver enzymes (aspartate aminotransferase, alanine aminotransferase), alkaline phosphatase, bilirubin, kidney function (blood urea nitrogen and creatinine), electrolytes, glucose, protein, albumin, and globulin at 0, 6, and 12 weeks.
Serum tocotrienol and tocopherol concentrations were assessed and pills counted at 0, 6, and 12 weeks. Quality of life, body composition, physical activity, and dietary macro: and micro-nutrient intake were evaluated at 0 and 12 weeks. A mixed model of repeated measures ANOVA was applied for analysis.
Results
Eighty seven subjects completed the study. Tocotrienol supplementation did not affect liver or kidney function parameters throughout the study. No adverse event due to treatments was reported by the participants. Tocotrienol supplementation for 6 weeks significantly increased serum delta-tocotrienol level and this high concentration was sustained to the end of study. There was no difference in serum delta-tocotrienol levels between the Low TT and the High TT groups. No effects of tocotrienol supplementation were observed on quality of life, body composition, physical activity, and nutrient intake.
Conclusions
Annatto-derived tocotrienol up to 600 mg per day for 12 weeks appeared to be safe in postmenopausal osteopenic women, particularly in terms of liver and kidney functions. Tocotrienol supplementation for 12 weeks did not affect body composition, physical activity, quality of life, or intake of macro: and micro-nutrients in these subjects.
Trial registration
ClinicalTrials.gov identifier: NCT02058420. Title: Tocotrienols and bone health of postmenopausal women.
Publication and source details
Original title: A 12-week evaluation of annatto tocotrienol supplementation for postmenopausal women: safety, quality of life, body composition, physical activity, and nutrient intake
Chwan-Li Shen; Shu Wang; Shengping Yang; Michael D. Tomison; Mehrnaz Abbasi; Lei Hao; Sheyenne Scott; Md Shahjalal Khan; Amanda W. Romero; Carol K. Felton; Huanbiao Mo
BMC Complementary and Alternative Medicine · 2018
© The Author(s). 2018https://creativecommons.org/licenses/by/4.0/Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.American River NutritionRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T19:05:40.743019+00:00
DOI: 10.1186/s12906-018-2263-0 · PMC6022510